These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 31429483)
1. Bacterial Type I CRISPR-Cas systems influence inflammasome activation in mammalian host by promoting autophagy. Wu Q; Wang B; Zhou C; Lin P; Qin S; Gao P; Wang Z; Xia Z; Wu M Immunology; 2019 Nov; 158(3):240-251. PubMed ID: 31429483 [TBL] [Abstract][Full Text] [Related]
2. Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade mammalian host immunity. Li R; Fang L; Tan S; Yu M; Li X; He S; Wei Y; Li G; Jiang J; Wu M Cell Res; 2016 Dec; 26(12):1273-1287. PubMed ID: 27857054 [TBL] [Abstract][Full Text] [Related]
7. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae. Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567 [TBL] [Abstract][Full Text] [Related]
8. CRISPR control of virulence in Pseudomonas aeruginosa. Wiedenheft B; Bondy-Denomy J Cell Res; 2017 Feb; 27(2):163-164. PubMed ID: 28084330 [TBL] [Abstract][Full Text] [Related]
9. Analysis of direct repeats and spacers of CRISPR/Cas systems type I-F in Brazilian clinical strains of Pseudomonas aeruginosa. Luz ACO; da Silva JMA; Rezende AM; de Barros MPS; Leal-Balbino TC Mol Genet Genomics; 2019 Oct; 294(5):1095-1105. PubMed ID: 31098740 [TBL] [Abstract][Full Text] [Related]
10. Characterization and applications of Type I CRISPR-Cas systems. Hidalgo-Cantabrana C; Barrangou R Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192 [TBL] [Abstract][Full Text] [Related]
11. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration. Xiao Y; Ng S; Nam KH; Ke A Nature; 2017 Oct; 550(7674):137-141. PubMed ID: 28869593 [TBL] [Abstract][Full Text] [Related]
12. Regulation of the CRISPR-Associated Genes by Rv2837c (CnpB) via an Orn-Like Activity in Tuberculosis Complex Mycobacteria. Zhang Y; Yang J; Bai G J Bacteriol; 2018 Apr; 200(8):. PubMed ID: 29378893 [TBL] [Abstract][Full Text] [Related]
14. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections. Gholizadeh P; Aghazadeh M; Asgharzadeh M; Kafil HS Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2043-2051. PubMed ID: 28601970 [TBL] [Abstract][Full Text] [Related]
15. Variability in the durability of CRISPR-Cas immunity. Chabas H; Nicot A; Meaden S; Westra ER; Tremblay DM; Pradier L; Lion S; Moineau S; Gandon S Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180097. PubMed ID: 30905283 [TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas Systems Optimize Their Immune Response by Specifying the Site of Spacer Integration. McGinn J; Marraffini LA Mol Cell; 2016 Nov; 64(3):616-623. PubMed ID: 27618488 [TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas systems: new players in gene regulation and bacterial physiology. Sampson TR; Weiss DS Front Cell Infect Microbiol; 2014; 4():37. PubMed ID: 24772391 [TBL] [Abstract][Full Text] [Related]
18. Investigation of direct repeats, spacers and proteins associated with clustered regularly interspaced short palindromic repeat (CRISPR) system of Vibrio parahaemolyticus. Baliga P; Shekar M; Venugopal MN Mol Genet Genomics; 2019 Feb; 294(1):253-262. PubMed ID: 30357478 [TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas Systems in Prokaryotes. Burmistrz M; Pyrć K Pol J Microbiol; 2015; 64(3):193-202. PubMed ID: 26638527 [TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Modell JW; Jiang W; Marraffini LA Nature; 2017 Apr; 544(7648):101-104. PubMed ID: 28355179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]